Humboldt Fund

Plus: Immunic eyes $240M private placement and updates from Applied Therapeutics and Novartis  

Plus: Keytruda approved for adjuvant NSCLC and updates for AZ’s Evusheld, BMS’s Breyanzi, Magenta, Theonys and more

Plus venture money for Vizgen, Watchmaker, Latch Bio, Endpoint Health

By using enzyme-cleavable linkers instead of blocking groups, Ansa can generate long, undamaged DNA molecules

With $175M in the bank, Fred Hutch spinout is adding synthetic biology switches to T cells to increase their tumor infiltration and persistence

Via $80M A round for manufacturing play, Bayer deepens its reach into next-gen cell therapy technologies

PFM, Farallon lead Bay Area biotech’s round to support pipeline, expand reach of gene editing systems

Vaccine developer Icosavax Inc. raised $100 million in a series B round led by RA Capital Management. New investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant

Coherus BioSciences Inc. (NASDAQ:CHRS) and Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) partnered to co-develop Junshi’s PD-1 inhibitor Tuoyi toripalimab in the U.S. and

Emerging Company Profile: Bay Area newco debuts with round led by Leaps by Bayer and Humboldt Fund